Role of cytoreductive surgery in recurrent ovarian cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 7, 2009, Pages 917-922

  Harter, Philipp ^a   Hilpert, Felix ^b   Mahner, Sven ^c   Kommoss, Stefan ^a   Heitz, Florian ^a   Du Bois, Andreas ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Ovarian cancer; Platinum sensitive ovarian cancer; Recurrent ovarian cancer; Secondary cytoreductive surgery; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ASCITES; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; HUMAN; LAPAROTOMY; OUTCOME ASSESSMENT; OVARY CANCER; POSTOPERATIVE PERIOD; PREDICTION; PROGNOSIS; RECURRENT CANCER; REOPERATION; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

EID: 69249175221     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.09.49     Document Type: Review

References (40)

1. Sharp F, Blackett AD, Leake RE, Berek JS. Conclusions and recommendations from the Helene Harris Memorial Trust fifth biennial international forum on ovarian cancer, May 4-7, 1995, Glasgow UK. Int. J. Gynecol. Cancer 5, 449-458 (1995).
2. Berek JS, Tropé C, Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann. Oncol. 10(Suppl. 1), 3-7 (1999).
3. Morris M, Gershenson DM, Wharton JT. Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy. Gynecol. Oncol. 33, 1-5 (1989).
4. du Bois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann. Oncol. 16(Suppl. 18),VIII7-VIII12 (2005).
5. Cormio G, di Vagno G, Cazzolla A et al. Surgical treatment of recurrent ovarian cancer: report of 21 cases and a review of the literature. Eur. J. Obstet. Gynecol. Reprod. Biol. 86, 185-188 (1999).
6. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88, 144-153 (2000).
7. Gadduci A, Iacconi P, Cosio S et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol. Oncol. 279, 344-349 (2000).
8. Gronlund B, Lundvall L, Christensen IJ et al. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete reponse to paclitaxel-platinum. Eur. J. Surg. Oncol. 31, 67-73 (2005).
9. Güngör M, Ortac F, Arvas M et al. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol. Oncol. 97, 74-79 (2005).
10. Harter P, du Bois A, Hahmann M et al. Surgery in recurrent ovarian cancer: the Arbeits gemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann. Surg. Oncol. 13, 1702-1710 (2006).
11. Jaenicke F, Holscher M, Kuhn W et al. Radical surgery procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70, 2129-2136 (1992).
12. Lichtenegger W, Sehouli J, Buchmann E, Karajanev C, Weidemann H. Operative results after primary and secondary debulking-operations in advanced ovarian cancer (AOC). J. Obstet. Gynaecol. Res. 24(6), 447-451 (1998).
13. Meier W, Romisch M, Hepp H. The value of reoperation in the treatment of ovarian cancer. Geburtshilfe Frauenheilkd. 53(1), 30-34 (1993).
14. Loehr A, Harter P, Traut A et al. Cytoreductive surgery in recurrent ovarian cancer. J. Cancer Res. Clin. Oncol. 130(Suppl. 1), 122 (2004) (Abstract OP570).
15. Morris M, Gershenson DM, Wharton JT et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol. Oncol. 34, 334-338 (1989).
16. Onda T, Yoshikawa H, Yasugi T et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br. J. Cancer 92, 1026-1032 (2005).
17. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 83, 504-512 (2001).
18. Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet. Gynecol. 99, 1008-1013 (2002).
19. Vaccarello L, Rubin SC, Vlamis V et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol. Oncol. 57, 61-65 (1995).
20. Zang RY, Zhang ZY, Li ZT et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J. Surg. Oncol. 75, 24-30 (2000).
21. Zang RY, Li ZT, Tang J et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100, 1152-1161 (2004).
22. Oksefjell H, Sandstad B, Tropé C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann. Oncol. 20, 286-293 (2009).
23. Harter P, Sehouli J, Reuss A et al. Predictive factors for resection in recurrent ovarian cancer. Intergroup study of AGO Kommission Ovar, Ago-OVAR, AGO Austria, MITO and NOGGO. Program and Abstracts of the 12th Biennial Meeting International Gynecologic Cancer Society. Bangkok, Thailand, 25-28 October 2008 (Abstract 38).
24. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent platinum-sensitive ovarian epithelial ovarian carcinoma. Cancer 106, 1933-1939 (2006).
25. McGuire WP, Hoskins WJ, Brady MF. Cyclophosphamide and cisplation compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1-6 (1996).
26. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21, 3194-3200 (2003).
27. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst. 92, 699-708 (2000).
28. duBois A, Lueck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paditaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst. 95, 1320-1329 (2003).
29. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Pfisterer J. The role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A combined exploratory analysis of three prospectively randomized Phase III multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115(6), 1234-1244 (2009).
30. Winter WE, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25, 3621-3627 (2007).
31. Winter WE, Maxwell GL, Tian C et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 26, 83-89 (2008).
32. Lenhard MS, Burges A, Johnson TRC et al. Predictive value of PET-CT imaging versus AGO scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer. Eur. J. Obstet. Gynecol. 140, 263-268 (2008).
33. Axtell AE, Lee MH, Bristow RE et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J. Clin. Oncol. 25, 384-389 (2007).
34. Salani R, Axtell A, Gerardi M et al. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol. Oncol. 108, 271-275 (2008).
35. Benedetti Panici P, De Vivo A, Bellati F et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann. Surg. Oncol. 4, 1136-1142 (2007).
36. Harter P, du Bois A. The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr. Opin. Oncol. 17, 505-514 (2005).
37. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/ AGO-OVAR-2.2 trial. Lancet 361, 2099-2106 (2003).
38. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin vs. carboplatin in platinum sensitive recurrent ovarian cancer. Results of a Gynecologic Cancer Intergroup randomized Phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. J. Clin. Oncol. 24, 4699-4707 (2006).
39. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol. Oncol. 112, 265-274 (2009).
40. Harter P, Hahmann M, Lueck HJ et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann. Surg. Oncol. 16, 1324-1330 (2009).